B+
Bull case
20%
Probability
Target price
$1.10
+128.3% vs current
KTTA
Pasithea TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$0.45
-6.6% vs current
B-
Bear case
25%
Probability
Target price
$0.18
-62.6% vs current
AI sentiment snapshot
Latest data as of 2026-07-15
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+59.5
Score
AI commentary
Primary-source company updates are constructive on tolerability, NF1 study expansion, and upcoming Q4 2026 data, but the stock remained near $0.48 as of 2026-07-14. There is no usable social or analyst-revision signal in the packet, so the positive clinical narrative should be treated as a monitoring hook rather than a confirmed rerating thesis.
RankAlpha Sentiment Codex - 2026-07-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventQ4 2026 interim NF1 data updateHigh impact
The Phase 1/1b NF1 study has enrolled and dosed 18 patients; protocol amendments added higher doses, longer treatment, and expanded imaging, with an interim data update targeted for Q4 2026 [#IR-2026-06-16].
2027-05-15catalystFinancing and runway checkpointHigh impact
The company remains development-stage and expects significant additional capital to fund clinical development, creating a recurring dilution and financing overhang despite near-term liquidity support [#SEC-10K-2026-03-30] [#SEC-10Q-2026-05-15].
2027-07-15catalystFollow-on PAS-004 advanced-cancer datasetHigh impact
June 2026 interim data reported 34 patients dosed, no dose-limiting toxicities, Grade 1–2 treatment-related adverse events, and durable stable disease in some heavily pretreated patients. Dose escalation continues, with a larger dataset planned for a future scientific conference [#IR-2026-06-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-15 • Updated nightlySource: Internal modelMethodology